FindTrial
Sign In

Phase III study of Garenoxacin in the treatment of community-acquired pneumonia- A randomized, multi-center, double-blind, double-dummy and comparative study-

Phase III study of Garenoxacin in the treatment of community-acquired pneumonia- A randomized, multi-center, double-blind, double-dummy and comparative study-

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221655
Enrollment
Unknown
Registered
2011-11-16
Start date
2011-11-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The patients with community-acquired pneumonia

Interventions

investigational material(s) Generic name etc : Garenoxacin 200 mg tablet INN of investigational material : Garenoxacin Therapeutic category code : 624 Synthetic antibacterials Dosage and Administratio

Sponsors

Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients with community-acquired pneumonia requiring outpatient or inpatient treatment. (2) Sex: male or female. (3) Age: 18 to 70 years old. (4) Pneumonia patients indicated to oral antibacterial agents. (5) Others.

Exclusion criteria

Exclusion criteria: (1)History of hypersensitive reaction to any quinolone antibacterial agents. (2) History of twitch and/or epilepsia or taking antiepileptic agents. (3) Pregnant females, females wishing to become pregnant or being possibly pregnant, and lactating females. (4) Patients with severe infection requiring tretment with injectable antibacterial agents or mechanical ventilator. (5) Others.

Design outcomes

Primary

MeasureTime frame
Clinical efficacy, bacteriological responses and safety Clinical efficacy, bacteriological responses and safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026